Key Drivers
- Exceptional gross margins
- Weak net profitability
- Stretched valuation
AIAI Summary
Pharming has shifted from a high‑risk R&D story into a commercial cash-generator where near-term value will be driven by execution—specifically Joenja uptake, RUCONEST retention, and disciplined capital allocation—rather than binary pipeline upside. The key actionable risk is the Joenja pediatric CRL (and attendant litigation/legal costs): monitor CRL remediation milestones, sequential Joenja US prescriptions/revenue trends, and OPEX control as the primary triggers that will validate or unravel the valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Exceptional gross margins
- •Weak net profitability
- •Stretched valuation
PHAR combines very high gross margins and strong cash/FCF with minimal net profitability, heavy operating spend, a large accumulated deficit, and stretched valuation implying limited near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Downward momentum
- •Nearby support
- •Resistance cap
PHAR is in a short-term downtrend over the last month, trading near the lower end of its range with support ~ $14.51 limiting near-term downside but resistance around $16.80 keeping sellers in control.
Price fell from $16.36 to $15.36 (~6%) over the last month, with rebounds repeatedly capped below prior highs
Sentiment & News
Key News Insights:
- •Revenue growth
- •RUCONEST strength
- •Shareholder lawsuits
Pharming reported strong 2025 momentum with full-year revenue up 27% (US$376.1M), driven by RUCONEST (up 26%) and rising Joenja demand, while facing new investor litigation.
Solid top-line and profitability underpin upside for the stock, but recent litigation raises near-term sentiment and legal risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings